- Home
- STTK vs CFSB Comparison
STTK vs CFSB Comparison
Compare STTK & CFSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- CFSB
- Stock Information
- Founded
- STTK 2016
- CFSB 1889
- Country
- STTK United States
- CFSB United States
- Employees
- STTK 44
- CFSB N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- CFSB Major Banks
- Sector
- STTK Health Care
- CFSB Finance
- Exchange
- STTK Nasdaq
- CFSB Nasdaq
- Market Cap
- STTK 48.9M
- CFSB 51.6M
- IPO Year
- STTK 2020
- CFSB N/A
- Fundamental
- Price
- STTK $1.02
- CFSB $13.90
- Analyst Decision
- STTK Hold
- CFSB
- Analyst Count
- STTK 5
- CFSB 0
- Target Price
- STTK $2.00
- CFSB N/A
- AVG Volume (30 Days)
- STTK 5.2M
- CFSB 1.1K
- Earning Date
- STTK 08-14-2025
- CFSB 08-26-2025
- Dividend Yield
- STTK N/A
- CFSB N/A
- EPS Growth
- STTK N/A
- CFSB N/A
- EPS
- STTK N/A
- CFSB N/A
- Revenue
- STTK $2,997,000.00
- CFSB $7,484,000.00
- Revenue This Year
- STTK N/A
- CFSB N/A
- Revenue Next Year
- STTK N/A
- CFSB N/A
- P/E Ratio
- STTK N/A
- CFSB N/A
- Revenue Growth
- STTK N/A
- CFSB N/A
- 52 Week Low
- STTK $0.69
- CFSB $6.34
- 52 Week High
- STTK $3.95
- CFSB $13.98
- Technical
- Relative Strength Index (RSI)
- STTK 61.64
- CFSB 64.64
- Support Level
- STTK $0.71
- CFSB $13.86
- Resistance Level
- STTK $1.05
- CFSB $13.91
- Average True Range (ATR)
- STTK 0.09
- CFSB 0.02
- MACD
- STTK 0.03
- CFSB -0.03
- Stochastic Oscillator
- STTK 69.18
- CFSB 46.67
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About CFSB CFSB Bancorp Inc.
CFSB Bancorp Inc provides banking services. It offers a variety of financial services to individuals and small businesses through its offices in Quincy, Holbrook, and Weymouth. Its primary deposit products are savings, checking, and term certificate accounts, and its primary lending product is residential mortgage loans.The Company's loan portfolio includes residential real estate, commercial real estate, construction, and consumer loan segments. Residential real estate loans include classes for one- to four-family, multi-family, second mortgages and home equity lines of credit.